Drug firm Marksans Pharma today said it has received Establishment Inspection Report (EIR) from the US health regulator for its Goa facility.
The company has received EIR from the United States Food and Drug Administration (USFDA) after inspection of its Goa facility from April 3-7, 2017, Marksans Pharma said in a BSE filing.
As per the USFDA, after the completion of an inspection of a facility, an EIR is issued to a company detailing inspectional findings.
Shares of Marksans Pharma were today trading 2.30 per cent higher at Rs 48.85 per scrip in the afternoon trade on BSE.
(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)